Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).

Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci (2016) 0.82

Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins. Oncotarget (2016) 0.75

The DNA damage response: ten years after. Mol Cell (2007) 11.80

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

Genomic instability in mice lacking histone H2AX. Science (2002) 10.23

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53

Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol (2003) 8.55

IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95

H2AX: the histone guardian of the genome. DNA Repair (Amst) (2004) 6.65

New nomenclature for chromatin-modifying enzymes. Cell (2007) 5.34

Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci U S A (2002) 5.07

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85

Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet (2003) 3.64

Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86

Isolation and characterization of Suv39h2, a second histone H3 methyltransferase gene that displays testis-specific expression. Mol Cell Biol (2000) 2.56

Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet (2014) 1.74

Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57

Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood (1993) 1.47

Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nat Rev Cancer (2015) 1.34

Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol (2008) 1.32

EZH2 in normal and malignant hematopoiesis. Leukemia (2013) 1.28

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia (2003) 1.23

Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11

Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol (2008) 1.09

Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair. Nat Commun (2014) 0.98

Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic. J Adolesc Young Adult Oncol (2011) 0.88

The treatment of adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2008) 0.87

Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia (2014) 0.86

New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol (2000) 0.85

Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma. Blood (2013) 0.84

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res (2015) 0.83

Alternative splicing regulates the expression of G9A and SUV39H2 methyltransferases, and dramatically changes SUV39H2 functions. Nucleic Acids Res (2015) 0.80

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs (2014) 0.80

Preface: acute lymphoblastic leukemia--quo vadis? Hematol Oncol Clin North Am (2009) 0.77

Treatment of childhood leukemias. Curr Opin Oncol (1995) 0.77

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol (2022) 0.75